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BACKGROUND. The incidence of breast cancer (BC)-related lymphedema (LE)
ranges from 7% to 47%. Successful management of LE relies on early diagnosis
using sensitive measurement techniques. In the current study, the authors
demonstrated the effectiveness of a surveillance program that included preopera-
tive limb volume measurement and interval postoperative follow-up to detect
and treat subclinical LE.
METHODS. LE was identified in 43 of 196 women who participated in a prospec-
tive BC morbidity trial. Limb volume was measured preoperatively and at 3-
month intervals after surgery. If an increase >3% in upper limb (UL) volume
developed compared with the preoperative volume, then a diagnosis of LE was
made, and a compression garment intervention was prescribed for 4 weeks.
Upon reduction of LE, garment wear was continued only during strenuous activ-
ity, with symptoms of heaviness, or with visible swelling. Women returned to the
3-month interval surveillance pathway. Statistical analysis was a repeated-mea-
sures analysis of variance by time and limb (P  .001) comparing the LE cohort
with an age-matched control group.
RESULTS. The time to onset of LE averaged 6.9 months postoperatively. The
mean (standard deviation) affected limb volume increase was 83 mL (119 mL;
6.5%  9.9%) at LE onset (P 5 .005) compared with baseline. After the interven-
tion, a statistically significant mean 48 mL (103 mL; 4.1%  8.8%) volume
decrease was realized (P < .0001). The mean duration of the intervention was 4.4
weeks (2.9 weeks). Volume reduction was maintained at an average follow-up
of 4.8 months (4.1 months) after the intervention.
CONCLUSIONS. A short trial of compression garments effectively treated subclini-
cal LE. Cancer 2008;112:2809–19. Published 2008 by the American Cancer
Society.*
KEYWORDS: breast cancer, lymphedema, early detection, physical therapy, early
intervention, compression, optoelectronic volumetry, subclinical lymphedema.
B reast cancer (BC)-related lymphedema (LE) is a chronic condi-tion that diminishes quality of life and contributes to impair-
ments in limb range of motion (ROM), loss of strength, and
functional limitations with activities, such as lifting and reaching.1–3
The frequency of BC-LE is approximately 33% to 47% after axillary
lymph node dissection (ALND) and radiation therapy (XRT)4–6 and
4% to 17% after sentinel lymph node biopsy (SLNB) and XRT.5,7–10
Other risk factors associated with the onset of BC-related LE include
obesity,11 postoperative infection,12 venapuncture9 to the affected
extremity, race, and level of hand use.9,13,14
Clinically apparent LE presents as visible or palpable tissue swel-
ling and may be associated with a perception of fullness and heavi-
ness in the limb.15–17 The progressive nature of LE requires life-long,
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costly treatment to control the condition and to pre-
vent associated secondary impairments, such as
infection, shoulder morbidity, and pain.13,18,19
Upper limb (UL) volume measurement is used
routinely to identify LE. Limb volume can be mea-
sured by using circumferential limb girth,20 water
displacement,21 optoelectronic perometry,22 and
bioelectrical impedance.23 These methods are reli-
able and valid to accurately quantify and monitor
LE; however, significant variability exists in their use
among research trials, prohibiting valid comparison
of incidence reports and treatment outcomes and,
thus, inhibiting extrapolation to the greater popula-
tion.9,21,24–30
Further disparity exists among the criteria used
to diagnose LE in clinical trials. Various diagnostic
definitions exist, including a difference between
limbs of >200 mL, >8% to 10%, and >2 cm and/or
subjective reports of limb heaviness.24,29,31–34 Armer
and Stewart report that these criteria are not inter-
changeable and cite 10% of limb volume change
from baseline as the most accurate threshold to diag-
nose clinically apparent LE.35 However, this is not
sufficiently discriminatory for diagnosis, because it
neglects to capture up to 150 mL of subclinical fluid
accumulation in the tissue.36,37 Detection and man-
agement of LE at this early stage may prevent the
condition from progressing to a chronic, disabling
stage18,38 and may enable a more cost-effective, con-
servative intervention.
The objective of the current case–control study
was to investigate the efficacy of a surveillance
method for the diagnosis and management of subcli-
nical LE in patients with early-stage BC. We hypothe-
sized that, on diagnosis of subclinical LE, a light-
grade compression garment worn daily for a short
trial would alleviate subclinical LE and eventually
could be discontinued.
MATERIALS AND METHODS
A large, observational, Institutional Review Board-
approved study (National Institutes of Health Proto-
col 02-CC-0044; National Naval Medical Center
[NNMC] Protocol B01-052) that was conducted at
the NNMC Breast Care Center (Bethesda, Md) from
2001 to 2006 used a surveillance model to identify
BC treatment-related morbidity. All women with
newly diagnosed, unilateral, early-stage BC (stage I-
III) were screened by a physical therapist preopera-
tively to determine eligibility. Patients were excluded
if they had a previous history of BC, bilateral BC, or
prior severe trauma or surgery of the affected UL. All
women who met the inclusion criteria and agreed to
participate were consented before participation
(n 5 196 patients). Bilateral UL strength, ROM, and
volume were assessed at the preoperative visit and
reassessed at 1 month, 3 months, 6 months, 9
months, 12 months, and 18 months postoperatively.
The surveillance model clinical pathway is illustrated
in Figure 1.
The inclusion criterion for this compression
intervention was a diagnosis of subclinical LE. Diag-
nostic criteria for LE included a volume increase
3% in the affected UL compared with the patient’s
preoperative measurement and with consideration of
the contralateral limb volume changes. The threshold
for diagnosis was set below the criteria currently out-
lined in the medical literature to facilitate early treat-
ment of LE before a clinically apparent onset.
Women were excluded from the intervention if they
experienced an onset of LE related to an infection or
blood clot (n 5 5 patients).
Through the surveillance trial, 43 women ages 34
to 82 years (mean  standard deviation [SD],
55.3  12.1 years) were diagnosed with subclinical
LE. An age-matched control group (CG) of women
without LE was selected from the trial for compari-
son. The CG was comprised of 43 women ages 33 to
81 years (mean  SD, 53.5  12.3 years). The physi-
cal characteristics of these groups are outlined in
Table 1. The groups were significantly different
FIGURE 1. Clinical pathway for the Prospective Physical Therapy Model of
Care. Med. indicates medical; Onc., oncology; Rad., radiation.
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physically for height (mean  SD, 1.66  0.06
meters hand dominance, and affected extremity
(P  .05).
Table 2 shows the BC-related characteristics of
the lymphedema group (LG) and the CG. No rando-
mization occurred, because as this was a population-
based morbidity trial. Women were included in the
LG upon LE diagnosis. Therefore, the CG highlights
treatment-based differences between the groups that
may be associated with LE onset. The reference peri-
ods for the CG were based on their 3-month interval
follow-up at 6 months, 9 months, and 12 months to
closely approximate the measurement times of the
LG. We classified lymph node dissection as only
SLNB (CG. n 5 0 patients; LG, n 5 5 patients), ALND
(CG, n 5 36 patients; LG, n 5 35 patients), or none
(CG, n 5 7 patients; LG, n 5 3 patients). Patients
with positive SLNB who went on to undergo comple-
tion ALND were included in the ALND group.
Measurements for both ULs were taken in a
standard position (Fig. 2A,B) with the Perometer
(Pero-System Messgerate, Wuppertal, Germany).22 UL
volume was calculated by using 80% of the total limb
length, which was measured from the ulnar styloid
process to the tip of the acromion for standardiza-
tion. Body weight was recorded at each visit to con-
trol for weight change.
Early Intervention
When women were diagnosed with LE, a conserva-
tive compression intervention was introduced. We
hypothesized that light-grade compression garments
worn daily for a short trial would alleviate subclinical
LE and eventually could be discontinued. The gar-
ment provided was a Jobst (BSN-Jobst, Inc., Charlotte,
NC) ready-made, 20- to 30-mm Hg compression
sleeve and gauntlet fitted by the physical therapist.
Two patients required custom-fitted garments
because their limbs exceeded in length the size range
of ready-made garments. Garments were prescribed
for daily wear, and women were advised to follow-up
for repeated measures in 1 month. No activity limita-
tions were placed on the patients for the duration of
the intervention.
At follow-up, when limb volume decreased as
indicated by the Perometer, women were advised to
continue wearing the garment only when completing
strenuous exercise or activity, during air travel, with
symptoms of heaviness, or if visible swelling
appeared.39–41 Women were instructed to follow-up
at their next interval 3 month surveillance visit
for repeated measures or sooner if symptoms were
exacerbated.
TABLE 1
Lymphedema Group and Control Group Physical Characteristics
Characteristic Mean6SD Range P*
Age, y .965
Control group 53.4  12.3 33–81
Lymphedema group 55.3  12.1 34–82
Baseline weight, kg .530y
Control group 69.7  16 46.7–137.9
Lymphedema group 71.8  14.3 48.1–105.3
Weight at intervention, kg .364
Control group 69.9  15.4 44.5–138.4
Lymphedema group 72.8  14.7 48.1–117.1
Weight at follow-up, kg .277
Control group 70  15.6 44–134.8
Lymphedema group 73.5  14.6 47.4–113.4
Height, m .017*
Control group 1.66  0.06 1.52–1.75
Lymphedema group 1.62  0.06 1.52–1.75
80% Arm length, cm .977
Control group 41.6  3.3 33.9–49.6
Lymphedema group 41.7  2.7 36–47.2
BMI at baseline, kg/m2 .135y
Control group 25.4  6 17.1–55.6
Lymphedema group 27.2  5 20–39.1
BMI at follow-up, kg/m2 .051y
Control group 25.6  5.9 16.2–54.3
Lymphedema group 27.9  5.1 19.1–40.3
Affected limb: No. of patients (%) .009{
Right
Control group 29 (67)
Lymphedema group 16 (37.2)
Left
Control group 14 (33)
Lymphedema group 27 (62.8)
Dominant limb: No. of patients (%) .018{
Right
Control group 17 (40)
Lymphedema group 28 (65.1)
Left
Control group 26 (60)
Lymphedema group 15 (34.9)
BMI classification: No. of patients (%)
Normal: <25 kg/m2
Control group 23 (53.5)
Lymphedema group 15 (34.9)
Overweight: 25–29.9 kg/m2
Control group 16 (37.2)
Lymphedema group 15 (34.9)
Obese: >30 kg/m2
Control group 4 (9.2)
Lymphedema group 13 (30.2)
SD indicates standard deviation; BMI, body mass index.
* P < .05 is significant with all interval data tested by univariate analysis of variance (ANOVA) at
baseline between groups.
y Weight and BMI were tested by repeated-measures ANOVA (baseline, onset of intervention, and
follow-up).
{ P < .05 is significant with nominal data tested by the chi-square test.
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Statistical Analysis
Statistical analyses were performed using SPSS soft-
ware (version 15.0; SPSS Inc., Chicago, Ill). A
repeated-measure 2 (LG vs CG) 3 3 (baseline, onset
of intervention, and follow-up) analysis of variance
(ANOVA) tested whether the means of the dependent
variables (affected limb volume and percent limb
TABLE 2
Control Group and Lymphedema Group: Breast Cancer-related
Characteristics
Characteristic
No. of patients (%)
PControl group Lymphedema group
Type of BC
DCIS 8 (18.6) 5 (11.6) .128
IDC 26 (60.5) 16 (37.2)
DCIS and IDC 6 (14) 15 (34.9)
Other 3 (7) 7 (16.1)
Stage of BC
0 8 (18.6) 3 (7) .024*
I 16 (37.2) 12 (27.9)
II 14 (32.5) 23 (53.5)
III 5 (11.6) 5 (11.6)
Surgery
MRM 21 (48.8) 19 (44.2) .522
BCT 21 (48.8) 24 (55.8)
Lymph node dissection
None 7 (16.3) 3 (7) .037*
ALND 36 (83.7) 35 (81.4)
SLNB 0 (0) 5 (11.6)
Radiotherapy
No 14 (32.6) 10 (23.3) .336
Yes 29 (67.4) 33 (76.7)
Hormone therapy
No 10 (23.3) 13 (30.2) .852
Yes 33 (76.7) 30 (69.8)
Chemotherapy
No 24 (55.8) 14 (32.6) .013*
AC 16 (37.2) 15 (34.9)
TAC 2 (4.7) 13 (30.2)
Other 1 (2.3) 1 (2.3)
Seroma
No 39 (90.7) 34 (79.1) .132
Yes 4 (9.3) 9 (20.9)
Axillary web syndrome
No 36 (83.7) 28 (65.1) .048*
Yes 7 (16.3) 15 (34.9)
No. of lymph nodes sampled .100y
Mean  SD, % 10.9  9.9 14.5  9.8
Range 0–37 1–48
Risk/lymph node sampled{ .112
Mean  SD, % 32  29.7 42.4  29.7
Range 0–111 0–144
No. of positive lymph nodes .320y
Mean  SD, % 1.2  4.4 2.4  6.2
Range 0–28 0–37
BC indicates breast cancer; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; MRM,
modified radical mastectomy; BCT, breast-conserving therapy; ALND, axillary lymph node dissection;
SLNB, sentinel lymph node biopsy; AC, doxorubicin, and cyclophosphamide; TAC, docetaxel (taxo-
tere), doxorubicin, and cyclophosphamide; SD, standard deviation.
* P  .05 is significant with nominal data tested using the chi-square test and ordinal data tested
using the Fisher exact test.
y Between-group differences were tested by univariate analysis of variance with P  .05 considered
statistically significant.
{ See Paskett 2007.14
FIGURE 2. (A and B) Standardized position for Perometer upper extremity
measurement.
TABLE 3
Time to Lymphedema Diagnosis, Intervention, and Follow-up
Variable
LE group only
Mean 6 SD Range
Time to diagnosis of LE, mo* 6.9  4.3 1–18
Duration of intervention, wk 4.4  2.9 2–12
Posttintervention follow-up, mo 4.8  4.1 2–24
LE indicates lymphedema; SD, standard deviation.
* Onset of intervention.
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volume change) were significantly different (P  .05)
over time for the LG compared with the CG. We also
calculated a relative risk for LE (Table 2), which we
defined according to Paskett et al, to identify the risk
(P < .05) of developing LE based on the number of
lymph nodes removed.14
RESULTS
Table 3 outlines the time trajectory of the onset,
intervention, and follow-up for the LG. Table 4 com-
pares UL volume changes (in milliliters and percents)
between the LG and the CG. Univariate ANOVAs
indicated that the 2 groups did not differ signifi-
cantly at baseline,(F1,84 5 1.187; P 5 .279). The aver-
age time from baseline (preoperative) to diagnosis of
subclinical LE was 6.9 months, during which time
the LG exhibited a statistically significant increase
(P < .001) in the volume of their affected limb. The
LG and CG limb volume changes over time are
exhibited in Figure 3. Changes in volume over time
differed significantly between the LG and the CG
(Wilks l, F3,82 5 4.608; P 5 .005 for group*time inter-
action) with a mean (SD) increase in limb volume
of 83 mL (119 mL) or 6.5% (9.9%) in the LG com-
pared with 2.7 mL (89 mL) or 0.5% (6.6%)
increase in the CG.
The LG had significantly higher UL volume than
the CG when the compression intervention was
introduced (F 5 4.596; P 5 .035). The average dura-
tion of the compression garment intervention was
4.4 weeks. During the follow-up period after the
intervention (mean, 4.8 months) a mean (SD) limb
volume decrease of 46 mL (103 mL) or 4.1%
(8.8%) was noted in the LG with activity-related
garment wear only (as described above) compared
with 2.3 mL (103 mL) or 0.7% (7.9%) decrease in
the CG (F 5 3.131; P 5 .080).
Although the body mass index (BMI) increased
over time for both the CG and the LG, the difference
was not significant between groups (Table 1). The LG
exhibited a higher BMI at baseline and at follow-up,
consistent with reports that correlate increased BMI
with the onset of LE.9,11
Using Paskett’s risk calculation, the LG demon-
strated a higher relative risk related to the number of
lymph nodes removed. However, that risk did not
differ statistically from the risk in the CG.
DISCUSSION
BC morbidity trials highlight the need for preopera-
tive measurement and prospective surveillance to
identify impairments.9,31,42,43 Early detection and
management of LE is an integral part of a surveil-
lance program.12,32,44,45 However, inconsistent and
inaccurate LE measurement techniques, along with a
lack of standard diagnostic criteria, have prevented a
surveillance model from becoming an accepted
standard of care.34,46,47 Recommendations for diag-
nostic standardization include using reliable and sen-
sitive measurement tools to detect volume change,
identifying a threshold value of volume change for
the diagnosis of LE, and obtaining preoperative vol-
ume measurements.20,24,31,34,48,49
The Perometer is a sensitive and standardized
device that uses infrared optoelectronic technology
to detect and quantify limb volume changes.22,29,31
Goltner et al reported that changes in interstitial tis-
sue congestion up to 150 mL may occur before limb
swelling is visible, and they quantified this volume
change by using optoelectronic perometry.50 Those
authors hypothesized, and we concur, that subclini-
TABLE 4
Comparison of Upper Limb Volume Changes (in mL and %) Between the Control and Lymphedema Groups at Baseline, Onset of Intervention,
and Follow-up
Variable
Control group: Mean 6 SD Lymphedema group: Mean 6 SD
PUL volume, mL Change, mL Change, % UL volume, mL Change, mL Change, %
Unaffected UL volume
Baseline 1253  295 1315  344 .375
Onset of intervention 1255  304 2  96 0.2  7.2 1328  355 13  76 1.1  6.7
Follow-up 1252  294 21.3  112 0.2  8.7 1341  351 26  83 2.2  7.3
Affected UL volume
Baseline 1256  291 1331  347 .005*
Onset of intervention 1259  288 2.7  89 0.5  6.6 1414  378 83  119 6.5  9.9
Follow-up 1258  279 2.3  103 0.7  7.9 1377  341 46  103 4.1  8.8
UL indicates upper limb; SD indicates standard deviation; UL, upper limb.
* P < .05 is significant upper limb volume for between group, baseline-affected, and baseline-unaffected upper limb volume tested by repeated-measures multivariate analysis of variance.
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cal interstitial congestion is the basis for patient-
reported sensory changes in the limb and is a pre-
cursor to the onset of LE. Similarly, we observed that
subclinical congestion is detectable in the limb and
that, when adequately managed with a conservative
compression intervention, the change is measurable
overtime.
Perometer software provides assessment of the
entire limb volume and the percentage difference
between limbs (Fig. 4) and allows for interlimb com-
parison over time.48 Figure 5A,B illustrates limb vol-
ume changes at the onset of subclinical LE
(accounting for weight gain) for 1 woman’s limbs.
Although this patient demonstrated increased limb
volume bilaterally because of weight gain, the
affected left limb volume increased nearly twice the
percentage increase of the unaffected right limb.
Neglecting to measure limb volume before BC
treatment introduces possible error in accurately
diagnosing LE. Pretreatment limb volume measure-
ment accounts for pre-existing normal interlimb var-
iance, which may range from 3% to 10%, depending
on arm dominance and activity level.51 An accurate
early diagnosis of LE cannot be made unless premor-
bid limb volume disparity is quantified and regular
follow-up is conducted to monitor limb volume
change. We demonstrated a statistically significant
change in limb volume in our cohort at the threshold
of 3%. Without accurate preoperative quantification
of normal interlimb variance, this meaningful subcli-
nical volume change will be missed.
Existing classification systems for LE fail to rec-
ognize a sensitive diagnostic threshold for subclinical
LE. A variety of incompatible grading systems have
FIGURE 3. Mean volume change over time in the affected limb versus the unaffected limb. Error bars are 1 standard deviation.
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evolved based on Stillwell’s 1969 LE classification
system, which defined significant LE as a >10% vol-
ume increase compared with the unaffected limb.52
These derivations include; the Common Terminology
Criteria for Adverse Events version 3 (CTCAEv3) (5%-
10% volume change), the Late Effects of Normal Tis-
sue/Subjective Objective Management and Analytic
Scale (2- to 4-cm girth difference at any point on the
limb), the International Society of Lymphology
(<20% minimal LE), and the American Physical
Therapy Association Guide to Physical Therapy Prac-
tice LE grading system (>2.5 cm girth change).48,53–55
Variability among scales contributes to inconsistent
incidence reports of LE and conflicting recommenda-
tions for treatment.
Optimal management of LE requires an accurate,
early diagnosis using a diagnostic threshold that is
sensitive to subclinical tissue changes. Armer et al
identify a threshold of 10% volume change as diag-
nostic for lymphedema. This correlates to approxi-
mately 200 mL volume change in the limb and is
associated with clinically apparent, symptomatic LE.
When applying this criterion, they report a 42% inci-
dence of BC-LE. Francis et al used a threshold of 5%
limb volume change to diagnose LE, as outlined in
the CTCAEv3 classification system,7,48 and reported
LE rates of 17% in patients who underwent SLNB
and 47% in patients who underwent ALND based on
preoperative limb measurements. These reports
demonstrate that incidence rates of LE are higher
than previously anticipated when a sensitive volu-
metric threshold is used for diagnosis and, thus, offer
a more accurate depiction of BC-related LE.
A new classification system is needed to recog-
nize subclinical lymphedema and encourage early
intervention to diminish the negative functional, cos-
metic, and psychosocial consequences of LE.6,56,57
On the basis of our findings, we believe that a more
sensitive threshold for diagnosing LE is warranted
and can be quantified by using optoelectronic ima-
ging technologies.36
The standard of care for treating and managing
clinically apparent LE is well established.55,58–60 How-
ever, to our knowledge there is no standard for the
treatment of early-stage, subclinical LE. When the di-
agnosis of LE is delayed, therapeutic management
requires intensive decongestive therapy and life-long
maintenance.61 Components of a decongestive ther-
apy program include skin care, compression ban-
dages, manual lymphatic drainage, garments, and
exercise administered over the course of several
weeks62,63 and require life-long maintenance to pre-
vent swelling exacerbations.64 This is burdensome
and expensive. Other methods for managing LE
include pneumatic compression devices, surgical
debulking, and laser therapy.55,65,66 Our patients
demonstrated a significant decrease in limb volume
and sustained volume maintenance using the com-
pression garments over a short duration.
We recommend preoperative screening with
postoperative follow-up using standardized measure-
ment techniques as the most effective means to
diagnose subclinical LE. Preoperative assessment is
vital to a surveillance protocol, because it identifies
normal interlimb variance, allowing for an accurate
assessment of postoperative volume changes consist-
ent with LE. Regular intervals of postoperative
follow-up enable early identification of LE and other
physical impairments resulting from BC-related
treatment.67 The average time to onset of LE in this
cohort was 6.9 months (SD  4.3; range. 1–18
months). Historic work by Petrek et al demonstrated
that the highest frequency of onset of LE occurred in
the first 3 postoperative years.68 Those findings sup-
port the contention that interval follow-up should
continue for the first postoperative year or lon-
ger.7,34,68
On the basis of this report, we define a 3% vol-
ume change from baseline as diagnostic criterion for
subclinical LE, requiring conservative intervention.
Furthermore, we propose a new grading system for
BC-LE that identifies a diagnostic threshold for sub-
clinical LE with recommendations for conservative
treatment (Table 5). This system relies on a prospec-
tive surveillance model to realize the benefit of early
identification and management of BC-LE.
Limitations
We recognize that this trial was limited because it
did not have a randomized-controlled design. In the
FIGURE 4. Upper limb volumes and circumferences (Circum.) from the
Perometer software.
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context of our morbidity trial, when LE was identi-
fied as an impairment, it was managed conserva-
tively with the intervention. The case–control design
of this study prevented us from controlling for many
of the BC treatment-related side effects that may
have contributed to the onset of LE and outcomes
identified with the compression trial.
In addition, we recognize that few clinical sites
have access to optoelectronic measurement technol-
ogy. However, in the absence of a Perometer, other
assessment tools, including; water displacement,
bioelectrical impedance analysis, circumferential
girth measurement, and subjective assessment tools,
when used in the context of a surveillance program,
FIGURE 5. Bilateral upper limb volumetric changes over time with the (A) left upper limb demonstrating subclinical lymphedema compared with the (B) right
upper limb.
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may prove efficacious in diagnosing subclinical LE.
Further research is warranted to validate those tools
in the context of a surveillance trial.
Implications for Practice
Preoperative baseline measurement is vital to suc-
cessfully diagnosing subclinical LE. However, cur-
rently, physical therapists in clinical practice rely on
an impairment-based model for diagnosing and
treating LE. This paradigm is inadequate if a subcli-
nical diagnosis is to be made. A shift in the current
practice pattern in favor of a surveillance model
is necessary and indicated based on the results
presented here. In the absence of a surveillance
program, the earliest diagnosis of LE will be missed.
In conclusion, preoperative assessment in the
context of a prospective surveillance model enables
the early detection and management of subclinical
LE. An early intervention protocol with 20- to 30-mm
Hg compression garments, as outlined in this report,
significantly reduces the affected limb volume to
near baseline measures and prevents progression to
a more advanced stage of LE for at least the first year
postoperatively. Further research is warranted to con-
firm the long-term clinical and cost effectiveness of
this surveillance model compared with a traditional
impairment-based model in treating BC-LE.
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TABLE 5
Proposed Classification of Secondary Lymphedema in Patients With Breast Cancer
Signs and symptoms Objective measure* Management
At risk of lymphedema
Impaired lymph transport because of removal/obliteration of
lymphatic nodes and vessels
Limb volume 0%–3% greater
than baseline
Education for risk reduction; education for signs and symptoms
of lymphedema; education for risk reduction
Grade 1: Subclinical lymphedema
Subclinical swelling is not clinically/visually evident but is
measurable objectively; subjective reports of limb heaviness,
aching, and numbness; protein-rich fluid
Limb volume 3%–5% greater
than baseline
Elastic sleeve (off the shelf or custom fit), 20–30 mm Hg with
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